Annual CFI
-$12.58 M
+$52.42 M+80.64%
31 December 2023
Summary:
Lyra Therapeutics annual cash flow from investing activities is currently -$12.58 million, with the most recent change of +$52.42 million (+80.64%) on 31 December 2023. During the last 3 years, it has fallen by -$10.81 million (-608.96%). LYRA annual CFI is now -33910.81% below its all-time high of -$37.00 thousand, reached on 31 December 2018.LYRA Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$8.14 M
-$28.04 M-77.50%
30 September 2024
Summary:
Lyra Therapeutics quarterly cash flow from investing activities is currently $8.14 million, with the most recent change of -$28.04 million (-77.50%) on 30 September 2024. Over the past year, it has increased by +$23.12 million (+154.35%). LYRA quarterly CFI is now -77.50% below its all-time high of $36.18 million, reached on 30 June 2024.LYRA Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$49.81 M
+$23.12 M+86.61%
30 September 2024
Summary:
Lyra Therapeutics TTM cash flow from investing activities is currently $49.81 million, with the most recent change of +$23.12 million (+86.61%) on 30 September 2024. Over the past year, it has increased by +$124.91 million (+166.34%). LYRA TTM CFI is now at all-time high.LYRA TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LYRA Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +80.6% | +154.3% | +166.3% |
| 3 y3 years | -609.0% | +1674.7% | +1563.9% |
| 5 y5 years | -10000.0% | +10000.0% | +10000.0% |
LYRA Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -609.0% | +80.6% | -77.5% | +112.5% | at high | +166.3% |
| 5 y | 5 years | <-9999.0% | +80.6% | -77.5% | +112.5% | at high | +166.3% |
| alltime | all time | <-9999.0% | +80.6% | -77.5% | +112.5% | at high | +166.3% |
Lyra Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.14 M(-77.5%) | $49.81 M(+86.6%) |
| June 2024 | - | $36.18 M(+360.4%) | $26.70 M(-365.8%) |
| Mar 2024 | - | $7.86 M(-433.1%) | -$10.04 M(-20.2%) |
| Dec 2023 | -$12.58 M(-80.6%) | -$2.36 M(-84.3%) | -$12.58 M(-83.2%) |
| Sept 2023 | - | -$14.98 M(+2570.1%) | -$75.09 M(+24.9%) |
| June 2023 | - | -$561.00 K(-110.6%) | -$60.15 M(+0.9%) |
| Mar 2023 | - | $5.32 M(-108.2%) | -$59.60 M(-8.3%) |
| Dec 2022 | -$65.01 M(+1820.4%) | -$64.87 M(>+9900.0%) | -$65.01 M(+5232.7%) |
| Sept 2022 | - | -$29.00 K(+107.1%) | -$1.22 M(-28.6%) |
| June 2022 | - | -$14.00 K(-84.9%) | -$1.71 M(-26.4%) |
| Mar 2022 | - | -$93.00 K(-91.4%) | -$2.32 M(-31.5%) |
| Dec 2021 | -$3.38 M | -$1.08 M(+109.5%) | -$3.38 M(-0.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$517.00 K(-17.3%) | -$3.40 M(-2.1%) |
| June 2021 | - | -$625.00 K(-46.1%) | -$3.48 M(+18.7%) |
| Mar 2021 | - | -$1.16 M(+5.4%) | -$2.93 M(+64.9%) |
| Dec 2020 | -$1.77 M(+741.2%) | -$1.10 M(+86.9%) | -$1.77 M(+135.4%) |
| Sept 2020 | - | -$589.00 K(+664.9%) | -$754.00 K(+330.9%) |
| June 2020 | - | -$77.00 K(+862.5%) | -$175.00 K(+4.8%) |
| Mar 2020 | - | -$8000.00(-90.0%) | -$167.00 K(-20.9%) |
| Dec 2019 | -$211.00 K(+470.3%) | -$80.00 K(+700.0%) | -$211.00 K(+61.1%) |
| Sept 2019 | - | -$10.00 K(-85.5%) | -$131.00 K(+8.3%) |
| June 2019 | - | -$69.00 K(+32.7%) | -$121.00 K(+132.7%) |
| Mar 2019 | - | -$52.00 K | -$52.00 K |
| Dec 2018 | -$37.00 K | - | - |
FAQ
- What is Lyra Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Lyra Therapeutics?
- What is Lyra Therapeutics annual CFI year-on-year change?
- What is Lyra Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly CFI year-on-year change?
- What is Lyra Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Lyra Therapeutics?
- What is Lyra Therapeutics TTM CFI year-on-year change?
What is Lyra Therapeutics annual cash flow from investing activities?
The current annual CFI of LYRA is -$12.58 M
What is the all time high annual CFI for Lyra Therapeutics?
Lyra Therapeutics all-time high annual cash flow from investing activities is -$37.00 K
What is Lyra Therapeutics annual CFI year-on-year change?
Over the past year, LYRA annual cash flow from investing activities has changed by +$52.42 M (+80.64%)
What is Lyra Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of LYRA is $8.14 M
What is the all time high quarterly CFI for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly cash flow from investing activities is $36.18 M
What is Lyra Therapeutics quarterly CFI year-on-year change?
Over the past year, LYRA quarterly cash flow from investing activities has changed by +$23.12 M (+154.35%)
What is Lyra Therapeutics TTM cash flow from investing activities?
The current TTM CFI of LYRA is $49.81 M
What is the all time high TTM CFI for Lyra Therapeutics?
Lyra Therapeutics all-time high TTM cash flow from investing activities is $49.81 M
What is Lyra Therapeutics TTM CFI year-on-year change?
Over the past year, LYRA TTM cash flow from investing activities has changed by +$124.91 M (+166.34%)